Clinical Trial of Vit D and Calcium for Recurrent BPPV

Not Applicable

Not yet recruiting

• Conditions: Vitamin D Deficiency; Dizziness; Dizziness; Epidemic; Benign Paroxysmal Positional Vertigo; Vertigo, Peripheral; Calcium Deficiency; BPPV; Vertigo
• Interventions: Dietary Supplement: vitamin D +/- calcium; Other: Placebo

• Registration Number: NCT05863949
• Lead Sponsor: Ottawa Hospital Research Institute

Brief Summary

Randomized double blind placebo controlled trial of vitamin D supplements, with or without calcium supplementation, versus placebo in reduction of recurrences in BPPV.

Detailed Description

Benign paroxysmal positional vertigo (BPPV) is the most common neuro-otological disorder, with a lifetime prevalence of 2.4 percent.1 BPPV is responsible for nearly one-half of cases of peripheral vestibular dysfunction. It is a highly recurrent disorder, with more than 1 in 4 patients experiencing a second attack, often within 6 months of the first.2-4 According to the Clinical Practice Guidelines for BPPV from the American Academy of Otolaryngology-Head and Neck Surgery Foundation, particle repositioning maneuvers (PRMs) are the only recommended treatment to resolve symptoms for both initial BPPV episodes as well as persistent episodes.5 While attacks can be effectively treated by PRMs, these often must be performed by a physician or other trained healthcare professional, and sometimes multiple attempts are required in order to successfully resolve a patient's symptoms. Furthermore, even with effective particle repositioning, a subset of patients may continue to experience bouts of recurrent attacks, up to several times yearly. The attacks themselves, as well as the nature of their treatment, - especially in patients with recurrent episodes - are prone to lead to interruptions in patients' daily activities, cause sick leaves, and result in significant direct and indirect costs to both the patient and the healthcare system.6 The prevalence of BPPV increases with age and elderly patients with BPPV are more likely to have reduced activities of daily living (ADL) scores, sustain falls, and suffer from depression.4,7 In the United States (US), more than sixty-five percent of patients with BPPV experience potentially avoidable diagnostic testing or therapeutic interventions during the time leading up to a proper diagnosis, costing the US health care system nearly $2 billion per year.5

BPPV is widely accepted to be caused by otoconia that are dislodged from the utricular macula into the semicircular canals - most commonly the posterior canal.8 Otoconia are made of a largely organic core of glycoproteins, with a predominantly inorganic periphery of calcium carbonate.9 Otoconia form within the otherwise low-calcium endolymph via an active, tightly controlled and ordered process.10 Recent studies have shown that the biomineralization of otoconia has similarities to that of bone and teeth, and that bone metabolism has a connection to BPPV. 11-13 Furthermore, an association has been demonstrated between BPPV and osteoporosis, and otoconia formation has been shown to be dysfunctional in animal models of osteoporosis.14,15

The impact of recurrent BPPV on both patients and the healthcare system is multiplicative. With each episode of recurrence, patients become symptomatic - potentially severely so - and must seek treatment again in the form of particle repositioning maneuvers. These patients therefore suffer further functional impairment, potentially missed school and work, and require healthcare interventions which are not without cost to the system. No preventative treatment option for recurrent BPPV exists. Establishing such a preventative treatment would have significant implications in reducing both direct and indirect costs of this highly prevalent and recurrent disorder.

Vitamin D is involved in bodily calcium regulation, and thus poses an attractive potential treatment for BPPV. Vitamin D deficiency is common in many regions worldwide, and supplementation carries little risk. A body of literature has emerged to date investigating potential links between vitamin D deficiency and BPPV - especially recurrent - and whether vitamin D supplementation could in turn serve some role in treatment or prevention.

Study Timeline

• Study First Submitted: 2023-04-28
• Status Verified: 2023-05
• Study First Submitted QC: 2023-05-08
• Last Update Submitted: 2023-05-08
• Study First Posted: 2023-05-18
• Last Update Posted: 2023-05-18
• Study Start: 2023-07
• Primary Completion: 2024-07
• Study Completion: 2025-07

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 860

Inclusion Criteria

• Age 18 years or older
• 2 or more distinct episodes of benign paroxysmal positional vertigo within a 12-month period on history
• At least 1 episode diagnosed based on physical examination by trained study personnel, meeting the diagnostic criteria of the Bárány Society
• Episodes separated in time, with a minimum of 1 week symptom-free between episodes
• Serum evidence of Vitamin D deficiency, as evidenced by 25-hydroxy vitamin D level of <75 nmol/L (<30 ng/mL)48
• Subject able to provide informed consent to participate in the study

Read More

Exclusion Criteria

Potential subjects will be excluded if they

• have another identifiable cause of vertigo identified on history or physical examination
• have a history of allergy or medically significant adverse reaction to vitamin D or calcium carbonate
• have a chronic medical disorder which is a contraindication to vitamin D or calcium carbonate supplementation, including uncontrolled hyperparathyroidism, nephrolithiasis, or GI malabsorption disorders
• are on loop diuretic agents or thiazides
• have a contraindication to routine bloodwork for study purposes, including being hospitalized with a critical illness, cellulitis at blood draw sites, or presence of vascular grafts.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
vitamin D +/- calcium supplementation	vitamin D +/- calcium	patients given Vitamin D 1000iu daily. Also given calcium 500mg BID daily if calcium deficient.
Placebo arm	Placebo	patients given 3 pills of placebo daily.

Primary Outcome Measures

Name	Time	Method
Recurrence rate of BPPV	1 year	how many recurrences of BPPV

Secondary Outcome Measures

Name	Time	Method
serum vitamin D levels (25(OH)D3)	1 year	serum vitamin D levels
time to serum vitamin D normalization	1 year	how long does it take patients to normalize
proportion of recurrences	1 year	what proportion of total patients have recurrences
EQ-5D	1 year	quality of life measurement
duration of recurrences	1 year	how long do recurrences of BPPV last
proportion of serum vitamin D normalization	1 year	do patients normalize
days per year of missed school/work	1 year	days per year of missed school/work